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Chronic angle -closure glaucoma (CACG) or pri-
mary angle -closure (PAC) and cataract often coex-
ist. Management of these conditions dependsmainly
on the control of intraocular pressure (IOP). In
cases where IOP severely rises, causes might be
appositional closure due to pupillary block, adhe-
sive closure due to extensive peripheral anterior
synechia, or combined glaucoma. Depending on
cases, we used laser iridotomy (LI) or peripheral
iridectomy to relieve pupillary block ; or glaucoma
surgery and/or cataract surgery. On the other hand,
in cases where IOP does not rise so severely, due
to early stage detection, only relief of pupillary block
is necessary to treat CACG or PAC. For eyes with
CACG (or PAC) and cataract, treatment involves
either LI followed by cataract surgery or primary
phacoemulsification and IOL implantation.
Many reports described that cataract extraction
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with posterior chamber IOL implantation decreased
IOP in eyes with angle -closure glaucoma (1-12).
Regarding the simultaneous use of phacoemulsifi-
cation plus IOL implantation for CACG, although
some reports demonstrated IOP reduction and
changes in the anterior chamber angle width and
depth, a few reports evaluated outcomes of phaco-
emulsification plus IOL implantation for CACG be-
fore the relief of pupillary block (4, 6, 8, 9, 12, 13).
We hereby report effects and safety of primary
phacoemulsification plus IOL implantation for the
control of CACG or PAC with cataract.
METHODS
This prospective study comprised 50 consecutive
eyes of 39 patients who were treated for CACG or
PAC between October 2003 and July 2005. Patients
with cataract, no history of previous ocular surger-
ies, and whose IOP was controlled with or without
anti -glaucoma medications were included in the
study. Due to the possibility of additional glaucoma
surgery, this prospective study did not include eyes
with uncontrolled CACG.
Diagnosis of CACG was made when slit - lamp
biomicroscopy showed a peripheral anterior cham-
ber as narrow as one third of the corneal thickness
or less using the van Herick method, and when
gonioscopy revealed Shaffer 1 or 2, and peripheral
anterior synechia without iritis and inflammatory
nodules. In addition, the presence of glaucomatous
optic disc excavation or visual field defects leads to
the diagnosis of CACG. Eyes without those glauco-
matous changes were diagnosed as PAC according
to the Japan Glaucoma Society guidelines for glau-
coma (14).
Following informed consent, patients chose pri-
mary phacoemulsification plus IOL implantation or
LI as a method to relieve pupillary block. As the
result, 27 eyes of 22 patients chose phacoemulsifi-
cation plus IOL implantation (IOL group), and 23
eyes of 17 patients chose LI (LI group). In the IOL
group, 15 eyes showed primary angle -closure glau-
coma, including 3 eyes with exfoliation syndrome.
The other 12 eyes showed no glaucomatous neu-
ropathy and were diagnosed PAC. In the LI group,
16 eyes showed primary angle -closure glaucoma,
including 2 eyes with exfoliation syndrome. The
other 7 eyes including 2 eyes with exfoliation syn-
drome were diagnosed PAC.
Two surgeons (H.H. and S.Y.) performed phaco-
emulsification plus IOL implantation. Operative pro-
cedures were as follows. Under topical anesthesia,
a 2.8 mm sclerocorneal tunnel was made. After con-
tinuous curvilinear capsulorhexis using a 25-gauge
bent needle, standard phacoemulsification was per-
formed. A posterior chamber IOL with a 6.0 mm
acrylic optic or a 5.5 mm polymethyl methacrylate
optic was implanted through a 4.1 -5.5 mm sclero-
corneal tunnel.
Meanwhile, LI using combined argon and Nd :
YAG laser surgery was performed as follows : sev-
eral shots of green laser light (power, 0.15 -0.2 W ;
spot size, 300 μm ; duration, 0.2 s), 50 -100 shots
with power of 0.85 -1 W, 50-μm spot size, and 0.02 -
s duration were done. Next, several pulses of Nd :
YAG laser with power of 1.3 -2.3 mJ were repeated
until a patent iridotomy was formed.
IOP and numbers of anti -glaucoma medications
were assessed in each group preoperatively, and 1,
2, 3, and 6 months postoperatively. IOP was meas-
ured using a Goldmann applanation tonometer. Pre-
operative and postoperative corneal endothelial cell
counts (Noncon Robo Specular Microscope, Konan)
were compared between each group. Cases that
failed to follow up at least 1 month were excluded
from the study.
Results were reported as means standard de-
viation. Statistical analyses used a parametric two-
group unpaired t-test, a parametric two-group paired
t -test, and a Fisher’s exact test. A P value .05 was
considered significant.
RESULTS
Preoperative patients’ demographics including
age, gender, and duration of follow-up did not sig-
nificantly differ between the two groups (Table 1).
Mean IOPs before treatment and 1, 2, 3 and 6
months after treatment are shown in Table 2 and
Table 1. Characteristics of patients
Characteristics IOL group LI group
Men/women 3/24 2/21
Mean ageSD
(range)
75.87.2*
(56-87*)
72.16.5*
(55-81*)
Mean follow-up
(range)
9.36.3* *
(1-21* *)
11.46.3* *
(1-23* *)
IOL = intraocular lens ; LI = laser iridotomy
* years
* * months
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Figure 1. There was no significant difference in
mean preoperative IOPs between the 2 groups.
Following treatment, mean IOPs in the IOL group
were significantly reduced from a preoperative mean
of 14.8  4.2 mmHg to a 6-month-postoperative
mean of 10.8  1.6 mmHg (P = .0276). In the LI
group, no significant difference in IOPs was found
between pre - and postoperative time (15.5 4.1
mmHg, vs 14.7  4.7 mmHg at 6 -months postop-
eration, P = .7591).
Table 3 shows mean numbers of anti -glaucoma
medications before and after treatment. There was
not a significant difference in preoperative mean
numbers between the 2 groups. No cases used
anti -glaucoma medications 6 months postopera-
tively in the IOL group ; whereas in the LI group,
mean number of anti -glaucoma medications de-
creased to 0.24  0.44 (P = .0093). Both groups
showed significantly reduced numbers of medica-
tions. No patients needed additional glaucoma sur-
gery.
One case in the IOL group showed infusion mis-
direction syndrome (15) during irrigation and as-
piration at the operation. However, in that case, an
IOL was inserted into the capsular bag, so that no
particular problems were seen after the operation.
One case showed slight hyphema after LI. How-
ever, hyphema disappeared within a few days, and
no anti -glaucoma medications and operation were
needed.
There were no significant differences in preop-
erative and postoperative corneal endothelial cell
counts between IOL and LI groups (P = .3922).
DISCUSSION
Treatments of eyes with CACG (or PAC) and
cataract involve simple relief of pupillary block us-
ing either LI, peripheral iridectomy, or phacoemul-
sification plus IOL implantation. In addition, glau-
coma surgery alone or glaucoma surgery combined
with cataract surgery may be performed.
Although many reports described that cataract
extraction with posterior chamber IOL implantation
decreased IOP in eyes with angle -closure glau-
coma (1-12), there are few reports on phacoemul-
sification and IOL implantation for CACG before
the relief of pupillary block (4, 6, 8, 9, 12, 13).
We found that primary phacoemulsification plus
IOL implantation significantly decreased IOP at
least 6 months after operation (Table 2, Figure 1),
indicating that IOL implantation not only relieved
pupillary block, but also reduced IOP. On the other
hand, LI did not reduce IOP within 6 months of
treatment. As the reason, we agree the view of
Hayashi K, et al. who think that IOL implantation
can make the anterior chamber wide and deep,
which may lead to the decrease of IOP (13). InFigure 1. Mean IOP over time
Table 3. Mean number of anti -glaucoma medications
Time of
examination
Mean numberSD
IOL group LI group P value
Preoperative 0.410.75
**
0.520.67
**
0.5735+
Postoperative (months)
1 0.040.19 0.220.42 0.0518+
2 0.040.20 0.180.40 0.1097+
3 0 0.210.42 0.0266*
6 0 0.240.44 0.0289*
P value 0.05* * 0.05* *
+ No significant difference
* Significant difference between the 2 groups
* * Significant difference between pre- and post operative time
Table 2. Mean IOP over time
Time of
examination
Mean IOPSD
IOL group LI group P value
Preoperative 14.84.2
**
15.54.1 0.4848+
Postoperative (months)
1 11.62.8 15.93.1 0.0016*
2 11.51.8 15.62.7 0.0002*
3 11.21.5 14.62.4 0.0009*
6 10.81.6 14.74.7 0.0369*
P value 0.05* * > 0.05+
+ No significant difference
* Significant difference between the 2 groups
* * Significant difference between pre- and post operative time
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addition, we think IOL implantation can relieve the
pupillary block completely where as LI may not
relieve it completely (16). Anyhow this result re-
vealed that LI was not effective as a glaucoma treat-
ment for IOP reduction at least in eyes with con-
trolled CACG.
However, both treated groups showed signifi-
cantly reduced numbers of medications (Table 3).
Therefore, IOL implantation and LI improved CACG
or PAC. Moreover, 3 and 6 months postoperatively,
no cases used anti -glaucoma medications in the
IOL group. This indicates that IOL implantation is
more effective in reducing the number of anti- glau-
coma medications than LI.
With respect to safety, we examined intraopera-
tive and postoperative complications including re-
duction in corneal endothelial cell counts.
As for intraoperative complications, only one case
in the IOL group showed infusion misdirection syn-
drome (15) during operation. Although an IOL
could be inserted into the capsular bag in this case,
care should be taken in avoiding zonular fiber dis-
order.
There were no significant differences in corneal
endothelial cell counts between IOL and LI groups
(Table 4), indicating that phacoemulcification plus
IOL implantation were as safe as LI. A long- term
study is desirable about the safty and effect of
these treatments to get the final conclusion.
CONCLUSION
Primary phacoemulsification plus intraocular lens
implantation for the control of CACG or PAC seems
to be a safe and effective method in reducing IOP.
Therefore, this procedure will become the first treat-
ment of choice for controlled CACG or PAC with
cataract.
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